Brussels/ Nantes, 7pm, November 7, 2007
Eurofins has unveiled a new ¤1million custom-built microbiology laboratory in Acton, west London. The new facility has been created in response to a significant rise in demand for analytical testing and represents a further step in Eurofins’ expansion within the UK.
Serving customers in the food and environmental sectors, the layout of the new lab has been designed to ensure the highest levels of quality and service to the company’s client base in the South of England, meeting the latest regulatory requirements.
The new laboratory is UKAS accredited and specialises in the microbiological analysis of food, beverage and environmental water samples, providing a wide variety of analytical tests including coliforms, streptococci and Legionella in addition to Salmonella, Listeria and spoilage organisms such as yeasts and moulds.
Eurofins will therefore also be able to focus on specialising laboratory activities and consolidating its existing network of four laboratories, in the South East, to three by mid 2008. The laboratories in Falmer and Otterbourne will concentrate on wet chemistry and organic testing respectively and Acton will assume the microbiology testing currently done at Chatham, Otterbourne and Falmer. Eurofins CEO, Dr Gilles Martin says, “Following the recent outsourcing of Southern Water’s laboratories to Eurofins, the new Acton facility will further enhance our leadership position in the UK analytical testing markets.”
Eurofins has also increased its logistics and drop off points in London and the South East. Together with offering a sample collection service, customers also have the benefit of drop-off points in South East London (Old Kent Road) South West London (Raynes Park) or West London (new Acton site).
For further information about Eurofins please visit www.eurofins.com or contact: Investor Relations Phone: +32-2-769 7383 E-mail: firstname.lastname@example.org
Notes for the editor: Eurofins - a global leader in bio-analysis Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors. With over 7,000 staff in more than 100 laboratories across 27 countries, Eurofins offers a portfolio of over 25,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to provide its customers with high quality services, accurate results in time and, if requested, expert advice by our highly qualified staff. The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both, its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international player in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the demands of regulatory authorities around the world. The shares of Eurofins Scientific are listed on Euronext in the Paris (ISIN FR0000038259) and Frankfurt (WKN 910251) Stock Exchanges (Reuters EUFI.LN, Bloomberg ERF FP, ESF, EUFI.DE).
Important disclaimer: This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.© Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
|EUROFINS SCIENTIFIC||Euronext Paris||394.50 (c)||0.19%||23 267|